---
layout: default
title: Selumetinib
parent: 僅模型預測 (L5)
nav_order: 569
evidence_level: L5
indication_count: 10
---

# Selumetinib
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Selumetinib: From NF1-Related Plexiform Neurofibroma to Familial Generalized Lentiginosis

## One-Sentence Summary

Selumetinib is a MEK1/2 inhibitor whose established use, per the evidence referenced in this pack, is NF1-related plexiform neurofibroma. The TxGNN model's top-ranked prediction is that it may also be effective for **Familial Generalized Lentiginosis**, but this specific pairing is currently supported by **0 clinical trials** and **0 publications** — it rests entirely on the model's similarity score to other RAS-MAPK-pathway diseases.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | NF1-related plexiform neurofibroma (referenced within this evidence pack's rationale data; no Taiwan-approved label text is available since the drug is not marketed here) |
| Predicted New Indication | Familial Generalized Lentiginosis |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L5 |
| Taiwan Market Status | 未上市 (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data for selumetinib is not available in this evidence pack (flagged as a High-severity data gap). Based on information available elsewhere in the pack, selumetinib is a MEK1/2 inhibitor — this is directly corroborated by literature cited under a different candidate indication (PMID 19804833, describing "MEK1/2 inhibitor AZD6244," selumetinib's development code) — and it is already used clinically for NF1-related plexiform neurofibroma, a RAS-MAPK-driven tumor.

The mechanistic rationale for familial generalized lentiginosis, as stated in the evidence pack, is that this pigmentary disorder shows clinical phenotype overlap with parts of the RASopathy spectrum (e.g., Noonan/LEOPARD-syndrome-related pigmentary disorders), which are themselves driven by dysregulated RAS-MAPK signaling. This creates a plausible hypothesis that MEK inhibition could be relevant.

However, the pack explicitly labels this as a **predictive link only, with no supporting empirical data** — the mechanistic overlap is inferred from phenotypic resemblance to a related disease group, not from any direct molecular or clinical study of familial generalized lentiginosis itself. This is markedly weaker than the mechanistic support seen for other candidates in the same prediction set (e.g., peripheral nerve schwannoma, rank 9, which has both a disease-specific Phase 2 trial and in-vitro MEK-inhibition data).

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## Safety Considerations

Please refer to the package insert for safety information.

## Cytotoxicity

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (MEK1/2 inhibitor) |
| Myelosuppression Risk | Not established in this evidence pack — please refer to the package insert |
| Emetogenicity Classification | Not established in this evidence pack — please refer to the package insert |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
- The disease-drug pair carries an L5 evidence level (decision stage S0) — no clinical trials, no literature, and a purely inferential mechanistic link based on phenotypic resemblance to other RASopathies. TFDA safety data (warnings/contraindications) is also a Blocking-severity gap, which by itself precludes any initial safety screening (S1).

**To proceed, the following is needed:**
- TFDA package insert data (warnings/contraindications) — currently a Blocking gap (DG001)
- Confirmed mechanism-of-action data via DrugBank API — currently a High-severity gap (DG002)
- Preclinical or mechanistic studies directly linking RAS-MAPK dysregulation to familial generalized lentiginosis pathogenesis (currently inferred only by analogy to LEOPARD/Noonan syndrome)
- Any case report, registry signal, or trial specifically enrolling patients with this disease

*Note: within this same prediction set, rank 3 (rhabdoid tumor, L3/S1) and rank 9 (peripheral nerve schwannoma, L3/S2) have materially stronger mechanistic and trial-based support and may be more productive candidates to prioritize ahead of this one.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

